A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
Petr Zatloukal, F. Cardenal, A. Szczęsna et al. · Annals of Oncology · 2010
Cited by 148 works. doi:10.1093/annonc/mdq036 Open-access PDF
Authors
- Petr Zatloukal
- F. Cardenal
- A. Szczęsna
- В. А. Горбунова
- Vladimir Mikhailovich Moiseyenko
- Laura A. Cisar
- Jean‐Charles Soria
- Manuel Dómine
- Michael Thomas
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer
- Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
- A useful testing strategy in phase iii trials: combined test of superiority and test of equivalence
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
- Small Cell Lung Cancer